Merck 2014 Annual Report Download - page 88

Download and view the complete annual report

Please find page 88 of the 2014 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 271

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186
  • 187
  • 188
  • 189
  • 190
  • 191
  • 192
  • 193
  • 194
  • 195
  • 196
  • 197
  • 198
  • 199
  • 200
  • 201
  • 202
  • 203
  • 204
  • 205
  • 206
  • 207
  • 208
  • 209
  • 210
  • 211
  • 212
  • 213
  • 214
  • 215
  • 216
  • 217
  • 218
  • 219
  • 220
  • 221
  • 222
  • 223
  • 224
  • 225
  • 226
  • 227
  • 228
  • 229
  • 230
  • 231
  • 232
  • 233
  • 234
  • 235
  • 236
  • 237
  • 238
  • 239
  • 240
  • 241
  • 242
  • 243
  • 244
  • 245
  • 246
  • 247
  • 248
  • 249
  • 250
  • 251
  • 252
  • 253
  • 254
  • 255
  • 256
  • 257
  • 258
  • 259
  • 260
  • 261
  • 262
  • 263
  • 264
  • 265
  • 266
  • 267
  • 268
  • 269
  • 270
  • 271

83GROUP MANAGEMENT REPORT → REPORT ON ECONOMIC POSITION → Review of forecast against actual business developments
Review of forecast against actual business developments in 2014
Guidance for 2014 provided in
Actual results
2013
€ million
Forecast 2014 in
Annual Report 2013 Q1 / 2014 Interim Report Q2 / 2014 Interim Report Q3 / 2014 Interim Report
Actual results 2014
€ million
Group
Sales 10,700
moderate increase,
slight organic growth € 10.9 –11.1 billion € 10.9 –11.1 billion € 11.0 –11.2 billion
11,291 (+ 5.5 /
+ 4.0 % org. /
+ 3.3 % acquisition)
EBITDA pre
one-time items 3,253 moderate increase € 3.3 – 3.4 billion € 3.3 – 3.4 billion € 3.3 – 3.4 billion
3,388
(+ 4.1 %)
Business
free cash flow 2,960 slight increase € 2.7 – 2.8 billion € 2.7 – 2.8 billion € 2.7 – 2.8 billion
2,605
(–12.0 %)
Earnings per share pre
one-time items1€ 4.39 – € 4.50 – 4.75 € 4.50 – 4.75 € 4.50 – 4.75
€ 4.60
(+ 4.8 %)
Biopharmaceuticals
Sales25,688
organic stable on a
comparable basis organic stable slight organic growth slight organic growth
5,783 (+1.7 % /
+ 3.6 % org.)
EBITDA pre
one-time items21,855
slight decline on a
comparable basis € 1.75 –1.85 billion € 1.75 –1.83 billion € 1.77 –1.83 billion
1,831
(–1.3 %)
Business
free cash flow21,787
moderate decline on a
comparable basis € 1.5 –1.6 billion € 1.5 –1.6 billion € 1.5 –1.6 billion
1,577
(–11.7 %)
Consumer Health
Sales2742
moderate increase on
a comparable basis
moderate organic
growth
moderate organic
growth
moderate organic
growth
766 (+ 3.2 % /
+ 5.4 % org.)
EBITDA pre
one-time items2172
moderate increase on
a comparable basis € 170 –180 million € 170 –180 million € 170 –180 million
169
(–1.7 %)
Business
free cash flow2172
slight increase on a
comparable basis € 150 –170 million € 150 –170 million € 150 –160 million
124
(– 28.1 %)
Performance Materials
Sales 1,642 significant increase slight organic growth slight organic growth slight organic growth
2,060 (+ 25.4 % /
+ 4.1 % org. /
+ 22.8 % acquisition)
EBITDA pre
one-time items 780 significant increase € 830 – 880 million € 850 – 880 million € 860 – 880 million
895
(+ 14.8 %)
Business
free cash flow 788 significant increase € 720 – 770 million € 720 – 770 million € 720 – 770 million
700
(–11.2 %)
Life Science
Sales 2,628 slight increase
moderate organic
growth
moderate organic
growth
moderate organic
growth
2,682 (+ 2.1 % /
+ 4.5 % org.)
EBITDA pre
one-time items 643 slight increase € 640 – 670 million € 640 – 670 million € 640 – 670 million
659
(+ 2.5 %)
Business
free cash flow 494 stable € 460 – 490 million € 460 – 490 million € 460 – 490 million
419
(–15.2 %)
Corporate and Other
EBITDA pre
one-time items –197 stable € –170 – – 200 million € –160 – – 190 million € –160 – –190 million
–166
(-15.5 %)
Business
free cash flow – 281 – ~ € – 240 million
€ – 200 – – 230 million € – 200 – – 220 million
–215
(- 23.7 %)
1 Based on the number of shares following the share split, which was approved by the Annual General Meeting on May 9, 2014.
2 Previous year’s figures have been adjusted, see “The Group” in the Group management report.